ImmunoGen enters strategic collaboration with Jazz Pharmaceuticals

ImmunoGen Inc. (Nasdaq: IMGN) entered a strategic collaboration agreement granting Jazz Pharmaceuticals (Nasdaq: JAZZ) exclusive, worldwide rights to develop and commercialize of two early-stage, hematology-related antibody-drug conjugate programs. Shares of ImmunoGen climbed $1.12 to close at $7.58 while Jazz Pharmaceuticals stock eased 23 cents to close at $145.86.